Table 2 Showing the role of HSCT and BMT in AIH
| Â | Patient main disorder | Patient gender | Donor | Transplanted cells | Results | Ref. |
|---|---|---|---|---|---|---|
HSCT | patient with SCD and AIH | Female | Patient’s HbSA haploidentical father | HSCT | - After HSCT by 2 years, the data showed a full donor hematopoiesis, no SCD manifestation was noted, cerebral vasculopathy appeared to be resolved and the patient required no additional medical treatment. Antinuclear and anti-smooth muscle autoantibodies were negative 2 months after HSCT, and there was no recurrence of AIH in the patient. | [89] |
BMT | Patient with a 4-year history of AIH and developed acute AL-L2. | Male | His healthy 25-year-old sibling was chosen as an MLC-non-reactive BM donor who was HLA A-, HLA B-, and DR-matched | - 6·8 × 108 bone marrow cells for each kilogram (overall 4·7 × 1010 cells) - 105 T lymphocytes for each kilogram body from a donor's peripheral blood (overall of 69 × 105 T lymphocytes) | - Allogeneic transplantation of BM and donor T cells resulted in the normalization of T-cell responses to ASGPR, the elimination of antibodies to the same autoantigen, and the noticeable treatment of AIH. | [90] |